Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 19/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4688697 | 0.92 | LTA4H (0.46) | LTA4HEPHX2KCNH2 | |
| Trifluoromethanesulfonic Acid SCHEMBL4694774 | 0.82 | LTA4H (0.43) | LTA4HEPHX2KCNH2 | |
| SCHEMBL2169428 | 0.81 | LTA4H (0.45) | LTA4HEPHX2KCNH2 | |
| SCHEMBL2168838 | 0.81 | LTA4H (0.44) | LTA4HEPHX2KCNH2 | |
| Trifluoromethanesulfonic Acid SCHEMBL4692567 | 0.80 | LTA4H (0.44) | LTA4HEPHX2KCNH2 | |
| SCHEMBL2168640 | 0.79 | LTA4H (0.47) | LTA4HEPHX2KCNH2 | |
| SCHEMBL4689565 | 0.79 | LTA4H (0.43) | LTA4HEPHX2KCNH2 | |
| SCHEMBL2168672 | 0.78 | LTA4H (0.55) | LTA4HEPHX2KCNH2PPARGPPARA | |
| SCHEMBL2167785 | 0.77 | LTA4H (0.52) | LTA4HEPHX2KCNH2 | |
| SCHEMBL2169174 | 0.76 | LTA4H (0.49) | LTA4HEPHX2KCNH2PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660492-B1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-20 | — | — | EP | disclosed |
| US-20080194630-A1 | Leukotriene A-4 hydrolase inhibitors; antiinflammatory agents; skin disorders; analgesics; stroke; anticancer agents; antiallergens; rhinitis;cystic fibrosis;sepsis | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-14 | — | — | US | disclosed |
| WO-2005012297-A9 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2007-01-04 | — | — | WO | disclosed |
| US-20050043379-A1 | LTA4H Modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | US | disclosed |
| US-20050043378-A1 | Leukotriene hydrolases inhibitors; antiinflamamtory agents; inflamamtory bowel disorders; antihistamines; chronic obstructive pulmonary diseases; multiple sclerosis; antiarthritic agents | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194630-A1 | Leukotriene A-4 hydrolase inhibitors; antiinflammatory agents; skin disorders; analgesics; stroke; anticancer agents; antiallergens; rhinitis;cystic fibrosis;sepsis | LTA4H, LTC4S, LTB4R | LTA4H 1/4885EPHX2 191/4885KCNH2 2161/4885 |
| US-20050043378-A1 | Leukotriene hydrolases inhibitors; antiinflamamtory agents; inflamamtory bowel disorders; antihistamines; chronic obstructive pulmonary diseases; multiple sclerosis; antiarthritic agents | LTA4H, LTC4S, LTB4R | LTA4H 1/4885EPHX2 365/4885KCNH2 4064/4885 |
| US-20050043379-A1 | LTA4H Modulators | LTA4H, LTB4R, LTB4R2 | LTA4H 1/4885EPHX2 101/4885KCNH2 3429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.